These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9157972)

  • 1. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
    Miquel K; Pradines A; Sun J; Qian Y; Hamilton AD; Sebti SM; Favre G
    Cancer Res; 1997 May; 57(10):1846-50. PubMed ID: 9157972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
    Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
    Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
    Vogt A; Sun J; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1997 Oct; 272(43):27224-9. PubMed ID: 9341167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.
    Stark WW; Blaskovich MA; Johnson BA; Qian Y; Vasudevan A; Pitt B; Hamilton AD; Sebti SM; Davies P
    Am J Physiol; 1998 Jul; 275(1):L55-63. PubMed ID: 9688935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
    Kusama T; Mukai M; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
    Clin Exp Metastasis; 2003; 20(6):561-7. PubMed ID: 14598891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells.
    Finder JD; Litz JL; Blaskovich MA; McGuire TF; Qian Y; Hamilton AD; Davies P; Sebti SM
    J Biol Chem; 1997 May; 272(21):13484-8. PubMed ID: 9153192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
    Sepp-Lorenzino L; Rosen N
    J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
    Lau CP; Huang L; Tsui SK; Ng PK; Leung PY; Kumta SM
    J Orthop Res; 2011 Mar; 29(3):403-13. PubMed ID: 20886653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.
    Pollack IF; Bredel M; Erff M; Hamilton AD; Sebti SM
    Neurosurgery; 1999 Nov; 45(5):1208-14; discussion 1214-5. PubMed ID: 10549939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
    Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.
    Bredel M; Pollack IF; Freund JM; Hamilton AD; Sebti SM
    Neurosurgery; 1998 Jul; 43(1):124-31; discussion 131-2. PubMed ID: 9657198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
    Doisneau-Sixou SF; Cestac P; Chouini S; Carroll JS; Hamilton AD; Sebti SM; Poirot M; Balaguer P; Faye JC; Sutherland RL; Favre G
    Endocrinology; 2003 Mar; 144(3):989-98. PubMed ID: 12586776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.
    Dan HC; Jiang K; Coppola D; Hamilton A; Nicosia SV; Sebti SM; Cheng JQ
    Oncogene; 2004 Jan; 23(3):706-15. PubMed ID: 14737105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.